Conference Coverage

Trend of Esophageal Squamous Cell Carcinoma in the 21st Century: An Analysis of the SEER 18 Database

Giri S, Pathak R, Aryal MR, Karmacharya P, Karki A.

Abstract 52: 2014 AVAHO Meeting


 

References

Purpose: Previous studies have shown declining overall trends of esophageal squamous cell carcinoma (SCC) in the U.S. and worldwide. We aimed to study the recent trends of this malignancy using a large national database.

Methods: We queried the Surveillance, Epidemiology and End-results (SEER) 18 database to identify the trends in the incidence of esophageal SCC in the U.S. from 2000-2011. Eligible patients were identified using SEER histology codes 8050-8089. Age-adjusted rates were plotted by time period, using a logarithmic scale for the ordinate. Gender and race specific trends were also plotted. Data analysis was done using SEER Stat 8.1.5, and trend analysis was done using Jointpoint regression program 4.1. Discussion: The incidence of esophageal SCC has continued to decline in early 21st century among both genders and across all races. The most prominent decline is being seen in black males and Asian/Pacific Islander females.

Results: A total of 344,408 cases of esophageal SCC were identified, 57.9% were males. Among the identified cases, 82.1% were white, 12.1% were black and 5.1% were other (American Indian, Alaska native, Asian/Pacific Islander). The age-adjusted incidence rates steadily decreased from 40.2/100,000 in 2000 to 34.0/100,000 in 2011 (annual percentage change [APC] -1.1, P < .05). Declining trends in incidence were seen in both sexes as well as across all races (white, black, American Indian/Alaska Native and Asian/Pacific Islander); however, this was most prominent in black males (APC -3.2, P < .05) and Asian/Pacific Islander females (APC -3.9, P < .05).

Recommended Reading

Implementation of the Cancer Care Coordination Program in the Veterans Affairs Hospital: Sharing Our Experience and What We Have Learned
Federal Practitioner
Using Reminder Dialog Templates to Monitor Cancer Care
Federal Practitioner
Reproducible Complete Remission of Advanced Hepatocellular Carcinoma With Sorafenib in Combination With Clopidogrel
Federal Practitioner
Systemic Therapy Use in Stage IV Pancreatic Cancer: Comparison Between VA Nebraska-Western Iowa and National Database, Using National Cancer Data Base Analysis
Federal Practitioner
National Cancer Care Cube
Federal Practitioner
Becoming a Paperless Radiation Oncology Department: LEAN Six Sigma Thinking in the VA System
Federal Practitioner
Evaluation and Implementation of a Standardized Approach to Supportive Care Management for Veterans Receiving Intravenous Chemotherapy
Federal Practitioner
Feasibility of Highly Efficient Linac-Based RapidArc Stereotactic Radiosurgery to Numerous Brain Metastases at Safe Background Dose
Federal Practitioner
Impact of Oncology Clinical Pharmacist Provider in a VA Oncology Clinic
Federal Practitioner
Demographic Disparities Related to First Course Treatment for Patients With Stage 2 Prostate Cancer at a VA Hospital And ACOS-Accredited Hospitals in the U.S.
Federal Practitioner